急性髓细胞白血病Bcl-2蛋白表达及其临床意义

目的：检测急性髓细胞白血病（AML）Bcl-2蛋白，并评价其与AML患者临床特征及多药耐药基因MDRl表达产物P170的关系。方法：免疫细胞化学ABC法检测白血病细胞中Bcl-2蛋白及P170表达。结果：AML中存在Bcl-2高水平表达，但复发的AML与初发AMLBcl-2表达无显著差异（P〉0．05）。初发AML中，Bcl-2阳性组患者完全缓解（CR）率显著低于Bcl-2阴性组（P〈O．01）。Bcl-2的阳性与阴性组中P170表达无显著差异（P〉0．05）。Bcl-2和P170间无相关表达（r1=0．171，P〉0．05），但Bcl-2／P170双阳性组化疗CR率显著低于双阴性组（P〈O．01）或P170／Bcl-2单阳性组（P〈O．05）。结论：初发AML中Bcl-2蛋白高水平表达与化疗耐药有关；Bcl-2与P170联合表达患者化疗反应更差。

Expression of Bcl-2 and P170 in acute myelocytic leukemia and clinical significance

Objective：To detect the expression of Bcl-2 in acute myelocytic leukemia（AML）,and evaluate the relationship between Bcl-2 and clinic characteristics of AML,and P170 product of multi-drug resistance genel （MDR1）. Method：Immunocytochemical ABC assay was adopted to detect Bcl-2 and P170 protein in the cells. Results：The higher expression of Bcl-2 was found in AML（P〈0.05）. But there was no significant difference of Bcl-2 expression between initial AML and relapsed AML（P〉0.05）. The higher expression of Bcl-2 in initial AML was closely related to the lower complete remission （CR） rate （P〈0.05）. The Bcl-2 expression was not correlated with the P170 expression in AML （r1= 0. 171 ,P〉0.05）. But the CR rate in Bcl-2 P170 both positive group was significantly lower than Bcl-2 or P170 positive group （P〈0. 05） or both negative group （P〈0. 01 ）. Conclusion：Bcl-2 and P170 can predict chemoresistance. The coexpression and P170 can predict chemoresistance more precisely.